<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249767</url>
  </required_header>
  <id_info>
    <org_study_id>Tret.2014.10.01.14</org_study_id>
    <nct_id>NCT02249767</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel</brief_title>
  <official_title>Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spear Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spear Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a double-blind, randomized, three-treatment, parallel study. Normal, healthy male
      and female children and adults (i.e., ages 12 to 40 years) with at least Grade 2 (i.e., mild
      severity) acne vulgaris were treated on the full face once daily for 84 days with the
      Tretinoin Gel 0.05%, Brand (tretinoin) Gel 0.05%, or Gel Vehicle. Acne lesions were graded by
      a single blinded observer at screening and at Weeks 0 (i.e., baseline), 2, 4, 8, and 12 at
      each location.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, randomized, three-treatment, parallel study conducted at three
      locations with a single investigator. Normal, healthy male and female children and adults
      (i.e., ages 12 to 40 years) with at least Grade 2 (i.e., mild severity) acne vulgaris were
      treated on the full face once daily for 84 days with the Tretinoin Gel 0.05%, Brand
      (tretinoin) Gel 0.05%, or Gel Vehicle. Acne lesions were graded by a single blinded observer
      at screening and at Weeks 0 (i.e., baseline), 2, 4, 8, and 12 at each location.

      The assigned study treatment was self-applied topically once daily for 84 consecutive days.
      Scheduled study visits included:

        -  Visit 1 (Baseline Visit, Day 0)

        -  Visit 2 (First Interim Visit, Day 14)

        -  Visit 3 (Second Interim Visit, Day 28)

        -  Visit 4 (Third Interim Visit, Day 56)

        -  Visit 5 (Forth Interim Visit, Day 84)

      A window of ± 4 days was considered acceptable for each scheduled visit following the
      Baseline Visit. Subjects were admitted into the study if they had a clinical diagnosis of
      acne vulgaris and if they met the inclusion/exclusion criteria. During the study visits, the
      following procedures were performed:

        -  Counts of inflammatory, non-inflammatory, and nodulocystic lesions

        -  The Investigator's Global Assessment (IGA)

        -  Assessment of application site reactions Safety was assessed by the monitoring of AEs
           and documenting signs and/or symptoms of application site reactions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Baseline Acne Lesions at Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Percent change in baseline in inflammatory and non-inflammatory lesions at week 12.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">574</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Generic Tretinoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of acne once daily over 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand Tretinoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of Acne once daily over 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment of acne once daily over 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin</intervention_name>
    <description>Treatment of acne once daily in evening</description>
    <arm_group_label>Brand Tretinoin</arm_group_label>
    <arm_group_label>Generic Tretinoin</arm_group_label>
    <arm_group_label>Placebo Vehicle</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal, healthy male and female children and adults aged 12 to 40 years

          -  Written and verbal informed consent had to be obtained. Subjects aged 12 to 17 years,
             had to sign an assent for the study and a parent or a legal guardian had to sign the
             informed consent

          -  Women of childbearing potential had to be non-pregnant and non-nursing, and had to be
             willing to avoid pregnancy during the course of the study and during the menstrual
             cycle following completion of their participation in the study. Adequate contraception
             was defined as systemic birth control, such as oral contraceptives, for three months
             prior and implantable/injectable contraceptives (e.g., Norplant, intrauterine device
             [IUD]) for six months prior to study drug administration; or barrier methods, such as
             diaphragm plus spermicide or condom plus spermicide, consistently for at least 14 days
             prior to study drug administration; or abstinence.

          -  On the face, having ≥ 20 inflammatory (i.e., papules and pustules) and ≥ 25
             non-inflammatory (i.e., open and closed comedones) lesions with ≤ 2 nodulocystic
             lesions (i.e, nodules and cysts), as per FDA Draft Guidance on Tretinoin, dated March
             20

          -  Able to refrain from the use of all other topical acne medications or antibiotics
             during the treatment period

          -  Considered reliable and capable of understanding their responsibility and role in the
             study

        Exclusion Criteria:

          -  Presence of any skin condition that would interfere with the diagnosis or assessment
             of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid
             folliculitis, or bacterial folliculitis). Note: Eczema and psoriasis on the body are
             not exclusions.

          -  Subjects with active cystic acne as evidenced by more than 2 facial nodules. Nodules
             are defined as in 7.3.3 as: deep-seated in the skin (i.e., centered in the dermis or
             subcutis) and greater than 5 mm in diameter.

          -  More than 40 papules and/or pustules (inflammatory lesions).

          -  More than 60 open and/or closed comedones/milia (non-inflammatory lesions).

          -  Overall severity grade of less than 2 or greater than 4.

          -  History of allergy or hypersensitivity to tretinoin, retinoids, or any of the study
             medication ingredients.

          -  Significant history or clinical evidence of auto-immune, cardiovascular,
             gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease.

          -  Use within 6 months prior to baseline of systemic retinoid (isotretinoin) treatment or
             therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are
             allowed).

          -  Oral contraceptives started or changed within 3 months prior to study initiation or
             planned to change during the study.

          -  Use on the face within 1 month prior to baseline of 1) cryodestruction or
             chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5)
             intralesional steroids, or 6) x-ray therapy.

          -  Use within 1 month prior to baseline of 1) spironolactone, 2) systemic steroids, 3)
             systemic antibiotics, 4) systemic treatment for acne vulgaris (other than oral
             retinoids, which require a 6-month washout), or 5) systemic anti-inflammatory agents.

          -  Use within 2 weeks prior to baseline of 1) topical steroids, 2) topical retinoids, 3)
             topical acne treatments including over-the-counter preparations, 4) topical
             anti-inflammatory agents, or 5) topical antibiotics.

          -  Pregnant or breast-feeding.

          -  Serious psychological illness.

          -  Significant history (within the past year) of alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moore Clinical Research</affiliation>
  </overall_official>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <results_first_submitted>December 28, 2019</results_first_submitted>
  <results_first_submitted_qc>December 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Generic Tretinoin</title>
          <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
        <group group_id="P2">
          <title>Brand Tretinoin</title>
          <description>Treatment of Acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
        <group group_id="P3">
          <title>Placebo Vehicle</title>
          <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="229"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not use medication</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Generic Tretinoin</title>
          <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
        <group group_id="B2">
          <title>Brand Tretinoin</title>
          <description>Treatment of Acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
        <group group_id="B3">
          <title>Placebo Vehicle</title>
          <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="222"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="549"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.1" spread="7.06"/>
                    <measurement group_id="B2" value="20.1" spread="7.60"/>
                    <measurement group_id="B3" value="19.6" spread="7.31"/>
                    <measurement group_id="B4" value="20.0" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="319"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="281"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Baseline Acne Lesions at Week 12</title>
        <description>Percent change in baseline in inflammatory and non-inflammatory lesions at week 12.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>This is Per protocol population (PP) Analysis. Generic Tretinoin Intent to Treat (ITT) started 222- 22 excluded as not following protocol= 200 PP. Brand Tretinoin 220 ITT - 11 excluded not following Protocol=209 PP. Placebo 107 ITT - 7 excluded = 100 PP Percent change from baseline in acne lesions</population>
        <group_list>
          <group group_id="O1">
            <title>Generic Tretinoin</title>
            <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
          </group>
          <group group_id="O2">
            <title>Brand Tretinoin</title>
            <description>Treatment of Acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
          </group>
          <group group_id="O3">
            <title>Placebo Vehicle</title>
            <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Baseline Acne Lesions at Week 12</title>
          <description>Percent change in baseline in inflammatory and non-inflammatory lesions at week 12.</description>
          <population>This is Per protocol population (PP) Analysis. Generic Tretinoin Intent to Treat (ITT) started 222- 22 excluded as not following protocol= 200 PP. Brand Tretinoin 220 ITT - 11 excluded not following Protocol=209 PP. Placebo 107 ITT - 7 excluded = 100 PP Percent change from baseline in acne lesions</population>
          <units>Percent reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.34" spread="30.35"/>
                    <measurement group_id="O2" value="-37.32" spread="28.81"/>
                    <measurement group_id="O3" value="-26.38" spread="32.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Treatment related irritation</desc>
      <group_list>
        <group group_id="E1">
          <title>Generic Tretinoin</title>
          <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
        <group group_id="E2">
          <title>Brand Tretinoin</title>
          <description>Treatment of Acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
        <group group_id="E3">
          <title>Placebo Vehicle</title>
          <description>Treatment of acne once daily over 12 weeks
Tretinoin: Treatment of acne once daily in evening</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Irritation from Drug</sub_title>
                <description>Irritation from drug as expected</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>With OK from Sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Spear</name_or_title>
      <organization>Spear Pharmaceuticals</organization>
      <phone>239-560-2411</phone>
      <email>spear@spearpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

